Drug Discovery
By
How is Bristol Myers Squibb Driving Growth After 2025’s Strategic Recalibration?
Bristol Myers Squibb (BMS) continues to build momentum in its post-loss-of-exclusivity strategy, with 2025 marked as a year…
Will Agios Pharma’s FDA Approval Expansion Drive a New Growth Phase in Blood Disorder Treatment?
Cambridge, Massachusetts | December 26, 2025 Agios Pharmaceuticals announced a major regulatory milestone after the U.S. Food and…
Novartis Builds on a Track Record of Expansion Ahead of the 2026 J.P. Morgan Healthcare Conference
Basel, Switzerland Novartis closed 2025 with sustained operational momentum, building on its transformation into a pure-play innovative medicines…
Regeneron to Present at 44th Annual J.P. Morgan Healthcare Conference
TARRYTOWN, N.Y. – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will webcast its presentation at the…
Can Eli Lilly’s 2025 Brand Launches and Label Expansions Redefine Leadership in Metabolic, Oncology, and Neuroscience Markets Beyond 2026?
Global | January 2026 — Eli Lilly and Company accelerated its transformation in 2025 through a series of…
Can Pfizer’s 2025 Brand Launches Across Vaccines, Oncology, and Specialty Care Reshape Its Growth Trajectory Beyond 2026?
Global | January 2026 — Pfizer Inc. advanced its post-pandemic transformation in 2025 through a series of targeted…
